European drug agency to appeal ruling that it stop releasing trial data
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i5331 (Published 30 September 2016) Cite this as: BMJ 2016;354:i5331- Nigel Hawkes
- London
The European Medicines Agency is at loggerheads with an EU court over the disclosure of trial data.
At the end of July the president of the EU General Court (a constituent court of the Court of Justice of the European Union) made interim orders prohibiting the agency from releasing a clinical study report on ataluren (which is marketed as Translarna), a drug for Duchenne muscular dystrophy, and three toxicology reports relating to fluralaner (Bravecto), a treatment for tick and flea infestations in dogs.
In both cases requests for the documents had been made by other drug companies and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £164 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.